1 link tagged with all of: a16z + pharma + clinical-trials + ai + biotech
Click any tag below to further narrow down your results
Links
The article argues that AI will revolutionize drug discovery long before it can streamline clinical development, creating an abundance of candidate molecules but leaving patient trials as the main constraint. As discovery becomes commoditized and more assets target the same biology, real value will hinge on predictive toxicity, clinical efficacy, and strategic trial design.